Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 2/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675366 | 0.81 | KIF11 (0.50) | TACR1KIF11FFAR1FFAR4GAA | |
| SCHEMBL22910539 | 0.81 | ALDH1A1 (0.51) | SLC6A4SLC6A2SLC6A3TACR1LTA4H | |
| SCHEMBL2395131 | 0.80 | KCNJ5 (0.49) | SLC6A4SLC6A2SLC6A3TACR1KIF11 | |
| SCHEMBL417693 | 0.80 | LTA4H (0.55) | SLC6A4SLC6A2SLC6A3TACR1LTA4H | |
| SCHEMBL5198493 | 0.79 | PDK2 (0.53) | TACR1KIF11FFAR1FFAR4GAA | |
| SCHEMBL8281063 | 0.79 | LTA4H (0.50) | SLC6A4SLC6A2SLC6A3LTA4HFFAR1 | |
| SCHEMBL18014699 | 0.78 | KIF11 (0.47) | SLC6A4SLC6A2SLC6A3TACR1KIF11 | |
| SCHEMBL9295043 | 0.77 | DPP4 (0.62) | TACR1KIF11FFAR1FFAR4HTR7 | |
| SCHEMBL22910534 | 0.77 | LTA4H (0.53) | SLC6A4SLC6A2SLC6A3LTA4HKCNH2 | |
| SCHEMBL5199432 | 0.77 | KIF11 (0.50) | TACR1KIF11FFAR1FFAR4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015089137-A1 | ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS | KAROS PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-1479671-B1 | Pyrimidinone compounds | SMITHKLINE BEECHAM PLC (GB) | 2009-05-27 | — | — | EP | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | SLC6A4 841/4885SLC6A2 830/4885SLC6A3 802/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | SLC6A4 841/4885SLC6A2 830/4885SLC6A3 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.